2017, Number 1
<< Back Next >>
Rev Sanid Milit Mex 2017; 71 (1)
Pulmonary hypertension of the newborn treatment
Arteaga-Mancera MP, Leboreiro-Iglesias J, Bernárdez-Zapata I, Rodríguez-Romero G, López-Cadena WA, Braverman-Bronstein A
Language: Spanish
References: 14
Page: 15-21
PDF size: 305.24 Kb.
ABSTRACT
Background: Persistent pulmonary hypertension of the newborn
(PPHN) has an incidence of 2-7 cases per 1000 live births. Currently
there are different treatment approaches for this disease, all of them
having similar results.
Objective: To describe thedifferent treatment approaches and the
evolution of patients with PPHN in the Neonatal Intensive Care Unit
(NICU) at the Spanish Hospital of Mexico.
Materials and methods: Retrospective descriptive study in
which the records of newborns diagnosed with PPHN in the NICU
Spanish Hospital of Mexico from January 2006 to September 2013
to obtain data on its evolution and treatment were reviewed. A nonprobability
sampling was done for convenience of newborns who met
the selection criteria during the study period.
Results: We included 80 newborns receiving care, 60% were men,
29% had pulmonary arterial hypertension mild, 61% moderate and
10% severe. The most commonly used method was conventional
mechanical ventilation (60%) and the most commonly used drug was
sildenafil (100%). 12.5% mortality and bronchopulmonary dysplasia
as a complication in 20% of cases was recorded.
Conclusion: Most newborns had a favorable outcome (73.7%) and
found that sildenafil is a drug recommended in the treatment of PPHN.
REFERENCES
Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell A. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007;120:e272-e282.
Farquhar M, Fitzgerald DA. Pulmonary hypertension in chronic neonatal lung disease. Paediatr Respir Rev 2010;11:149-153.
Aggarwal S, Natarajan G. Echocardiographic correlates of persistent pulmonary hypertension of the newborn. Early Hum Dev 2015;91:285-289.
Nair PMC, Bataclan MF. Persistent pulmonary hypertension of the newborn. Saudi Med J 2004;25:693-699.
Dhillon R. The management of neonatal pulmonary hypertension. Arch Dis Child Fetal Neonatal Ed 2012;97:F223- F228.
Porta NF, Steinhorn RH. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents. Clin Perinatol 2012;39(1):149- 164.
7Storme L, Aubry E, Rakza T, Houeijeh A, Debarge V, Tourneux P, et al. Pathophysiology of persistent pulmonary hypertension of the newborn: impact of the perinatal environment. Arch Cardiovasc Dis 2013;106:169-177.
Jain A, McNamara PJ. Persistent pulmonary hypertension of the newborn: advances in diagnosis and treatment. Semin Fetal Neonatal Med 2015; 20(4):262-271.
Bendapudi P, Rao GG, Greenough A. Diagnosis and management of persistent pulmonary hypertension of the newborn. Paediatr Respir Rev 2015:5-9.
Iacovidou N, Syggelou A, Fanos V, Xanthos T. The use of sildenafil in the treatment of persistent pulmonary hypertension of the newborn: a review of the literature. Curr Pharm Des 2012;18:3034-3045.
Nair J, Lakshminrusimha S. Update on PPHN: Mechanisms and treatment. Semin Perinatol 2014;38:78-91.
Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol 2012;32(8):608-613.
Shah P, Ohlsson A. Sildenafil para la hipertensión pulmonar en neonatos. Cochrane Database System Rev 2011;8:CD005494. DOI: 10.1002/14651858.CD005494.
Gitto E, Pellegrino S, Aversa S, Romeo C, Trimarchi G, Barberi I, et al. Oxidative stress and persistent pulmonary hypertension of the newborn treated with inhaled nitric oxide and different oxygen concentrations. J Matern Fetal Neonatal Med 2012;25(9):1723-1726.
Full text